Genus Biosystems Inc.
Northbrook, IL
- UEI
- YUS9H4YC76E7
- CAGE
- 4EPC8
- Primary NAICS
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 1808 Janke Dr, Northbrook, IL 60062, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $0 |
| FY2024 | $61,306 |
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Expression Analysis | Durham, NC | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Medgenome Inc. | Foster City, CA | 621511 Medical Laboratories |
| Labcorp Genetics Inc. | Burlington, NC | 621511 Medical Laboratories |
| Integrated Genetics And Integrated Oncology Business Units | Westborough, MA | 621511 Medical Laboratories |
| Singulomics Corp | NY | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
Genus Biosystems Inc. is a for-profit organization registered to receive federal contract awards since May 22, 2006. The company specializes in providing laboratory testing services, particularly in the field of genomics and transcriptomics, to federal agencies. Genus Biosystems Inc. primarily conducts business with the Department of Health and Human Services, specifically the National Cancer Institute, offering services that support cancer research and treatment optimization. The company's expertise appears to lie in microarray profiling and analysis of genetic material, which is crucial for advancing understanding of cancer biology and treatment responses.
Recent federal contract awards to Genus Biosystems Inc. demonstrate its focus on providing specialized laboratory services. In May 2024, the company was awarded a $23,520 purchase order for general lab testing services by the National Cancer Institute. A more specific contract from February 2024, valued at $37,785.60, involved mRNA and microRNA microarray profiling services aimed at predicting radiation therapy outcomes for cancer patients. This indicates the company's involvement in cutting-edge research that could potentially improve cancer treatment strategies. An earlier contract from September 2019, worth $38,179.20, also suggests ongoing collaboration with the National Cancer Institute, though specific details of this project are not provided. Notably, none of these contracts were associated with any set-aside designations, implying that Genus Biosystems Inc. competes for these awards in the open market based on its specialized capabilities in genomic and transcriptomic analysis.
Quick answers
Is Genus Biosystems Inc. registered in SAM.gov?
Yes. Genus Biosystems Inc.'s SAM.gov registration is active through March 11, 2027.
What is Genus Biosystems Inc.'s CAGE code?
Genus Biosystems Inc.'s CAGE code is 4EPC8, and its Unique Entity ID (UEI) is YUS9H4YC76E7.
How much has Genus Biosystems Inc. received in federal contracts?
Federal contracts obligated $61,306 to Genus Biosystems Inc. in fiscal years 2023 through 2027.
What is Genus Biosystems Inc.'s most recent federal award?
Genus Biosystems Inc.'s most recent federal contract award is Lab testing services (75N91024P00336), from National Cancer Institute (NIH), on May 1, 2024.
On GovTribe
See Genus Biosystems Inc.'s full federal record
- Federal contract awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors